CCM
ADPT icon

Coldstream Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Coldstream Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,655
Closed -$12.3K – 1141
2025
Q1 		$12.3K Buy
+1,655
New +$12.7K ﹤0.01% 2301

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's ADPT Position: Q2 2025 in Review

Coldstream Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2025, closing a stake of 1,655 shares — an estimated $12.3K sold.

Coldstream Capital Management first reported a position in ADPT in Q1 2025 and held it in 1 quarter. The position peaked at $12.3K in Q1 2025. 242 funds tracked by Wall St. Rank hold ADPT as of Q2 2025.

  • Coldstream Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,655 Adaptive Biotechnologies shares in Q2 2025, an estimated $12.3K.
  • Coldstream Capital Management first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Adaptive Biotechnologies position peaked at $12.3K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.